Effects of repeated-dose isradipine on the abuse liability of cocaine

John D. Roache, Bankole A. Johnson, Nassima Ait-Daoud, James B. Mauldin, Joe E. Thornton, Lynda T. Wells, William L. Murff

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Despite preclinical studies suggesting that isradipine may antagonize the abuse liability of cocaine, pretreatment with sustained-release isradipine did not reduce euphoric mood in cocaine-using volunteers. This double-blind, within-subject, crossover laboratory study determined whether maximal dose-loading with isradipine could antagonize effects of cocaine in 12 cocaine-dependent research volunteers administered intravenous cocaine doses (0, 0.325, and 0.65 mg/kg) on different days after 5 days of treatment with isradipine or placebo. Isradipine dose was 30 mg sustained release nightly plus 15 mg immediate release 2 hr before cocaine infusion. Cocaine produced dose-related increases in cocaine's subjective effects and a behavioral measure of reinforcement. Isradipine enhanced, rather than antagonized, subjective effects, indicating that isradipine does not antagonize cocaine's abuse liability in dependent research volunteers.

Original languageEnglish (US)
Pages (from-to)319-326
Number of pages8
JournalExperimental and Clinical Psychopharmacology
Issue number4
StatePublished - Nov 2005


  • Calcium channel antagonist
  • Cocaine
  • Drug abuse
  • Isradipine
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'Effects of repeated-dose isradipine on the abuse liability of cocaine'. Together they form a unique fingerprint.

Cite this